Showing 291 - 300 of 685 for "Bun %26 Associates" with applied filters
16 January 2024 by
The exclusive right of a patentee to stop others from making or using their invention for a defined period is balanced by the obligation to disclose the invention in detail.
05 January 2024 by
Barely a week ago on December 29, 2023, China’s legislative body passed and President Xi Jinping signed into law the newly revised Company Law, effective from July 1, 2024 (the “New Law”).
04 January 2024 by
Driven by the passion and belief, and fraught with various risks and challenges, the research and development of innovative drugs and medical devices is a journey that’s never easy.
03 January 2024 by
ESG is in high alignment with China’s “dual carbon” goals and has become an important indicator for measuring the sustainable and high-quality development of enterprises in China
03 January 2024 by
Wu Dong of Hui Ye Law Firm discusses the key points necessary for understanding the foreign acquisition of Chinese state-owned enterprises
21 December 2023 by
The Delhi High Court, in F Hoffmann-La Roche & others v. Drugs Controller General of India & others (2023:DHC:6522), dismissed applications filed by Cadila Healthcare and Hetero Drugs seeking rejection of the plaints in Roche’s suits
15 December 2023 by
VILAF announces promotion of new partner Tung Nguyen
30 November 2023 by
A couple of months back, the Ministry of Commerce and Industry published the Draft Patents (Amendment) Rules,2023, with various changes to the rules, regulations and fees, which welcomed suggestions and objections from the public.
20 November 2023 by
After the milestone verdict of the Delhi High Court in Allergan v Controller (2023:DHC:515), now it is time for patent strategists to rejoice over landmark judgments of the Madras High Court, including Starpharma Pty Ltd. v Controller (2023/MHC/4638) that provide similar liberal interpretations of amendment of claims under Section 59 of the Patents Act, 1970.
13 November 2023 by
10 November 2023 | New Delhi: Shardul Amarchand Mangaldas advised Ring Plus Aqua Limited (“RPAL”) on the strategic acquisition of 59.25% stake in Maini Precision Products Limited (“MPPL”), an entity engaged in the business of manufacturing
